keyword
https://read.qxmd.com/read/38148101/ivig-as-a-promising-therapy-for-methotrexate-induced-life-threatening-neutropenic-enterocolitis-in-an-elderly-patient-with-rheumatoid-arthritis-a-case-report-and-literature-review
#21
JOURNAL ARTICLE
Shan-Wen Lui, Jeng-Wei Lu, Yi-Jung Ho, Ting-Yu Hsieh, Fu-Chiang Yeh, Feng-Cheng Liu
BACKGROUND/AIM: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with the functional impairment of multiple joints and the destruction of bone and cartilage. Methotrexate (MTX) is a first-line drug commonly used to treat RA; however, even low doses of MTX can potentially cause rare but severe adverse reactions, such as neutropenic enterocolitis (NE), a life-threatening disease characterized by intestinal mucosal damage and immunodeficiency. CASE REPORT: Here, we report on an 82-year-old RA patient who developed life-threatening NE after ten years of low-dose MTX treatment...
2024: In Vivo
https://read.qxmd.com/read/38124710/a-case-of-idiopathic-multicentric-castleman-s-disease-with-secondary-autoimmune-neutropenia
#22
Toshiki Morimoto, Takako Kawaguchi, Kei Yamasaki, Tatsuya Shingu, Hiroaki Ikegami, Hiroki Dosaka, Yuichi Murata, Yoshinori Kawabata, Kazuhiro Yatera
A 73-year-old Japanese woman with productive cough and dyspnoea on exertion was admitted, and she showed neutropenia and pulmonary reticular opacities and axial and mediastinal lymphadenopathies on chest computed tomography. The clinical findings and surgical lung and lymph node biopsies were diagnostic for idiopathic multicentric Castleman's disease (iMCD) complicated by secondary autoimmune neutropenia (AIN). iMCD is often complicated with hematologic disorders, however, iMCD complicated with AIN has not been reported; therefore, if iMCD is accompanied by neutropenia, the anti-neutrophil antibodies should be measured...
January 2024: Respirology Case Reports
https://read.qxmd.com/read/38105745/the-complex-relationship-between-large-granular-lymphocyte-leukemia-and-rheumatic-disease
#23
REVIEW
Tony Marchand, Thierry Lamy
INTRODUCTION: Large granular lymphocytic (LGL) leukemia is a rare lymphoproliferative disorder characterized by an expansion of clonal T or NK lymphocytes. Neutropenia-related infections represent the main clinical manifestation. Even if the disease follows an indolent course, most patients will ultimately need treatment in their lifetime. Interestingly, LGL leukemia is characterized by a high frequency of autoimmune disorders with rheumatoid arthritis being the most frequent. AREAS COVERED: This review covers the pathophysiology, clinic-biological features and the advances made in the treatment of LGL leukemia...
December 18, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37954540/a-rare-presentation-of-vanishing-bile-duct-syndrome-in-hodgkin-lymphoma-case-report
#24
Bharat Patodiya, Vinod K Ramani, Padaki Nagaraja Rao, Mithun Sharma, Shalini Patodiya, D Nageshwar Reddy
In this report, we present the case of vanishing bile duct syndrome in the setting of classical Hodgkin lymphoma. Vanishing bile duct syndrome was diagnosed retrospectively in this patient with Hodgkin lymphoma, who initially presented with a hepatic abnormality presumed to be drug induced. Vanishing bile duct syndrome is characterized by the disappearance of bile ducts, with the progressive damage resulting in cholestasis. Thus, nivolumab therapy was initiated for Hodgkin lymphoma, in place of the standard ABVD (Doxorubicin, bleomycin, vinblastine, dacarbazine) regimen, which resulted in autoimmune hemolytic anemia...
2023: SAGE Open Medical Case Reports
https://read.qxmd.com/read/37953670/splenectomy-outcomes-in-immune-cytopenias-treatment-outcomes-and-determinants-of-response
#25
JOURNAL ARTICLE
Olisaemeka D Ogbue, Waled Bahaj, Tariq Kewan, Ramsha Ahmed, Danai Dima, Nakisha Willimas, Arda Durmaz, Valeria Visconte, Sara M Maskal, Carmelo Gurnari, Rosenblatt Steven, Jaroslaw P Maciejewski
BACKGROUND: Splenectomy is commonly used to treat refractory immune-mediated cytopenia, but there are no established factors that are associated with response to the procedure. OBJECTIVES: A cohort study was conducted to evaluate the hematologic and surgical outcomes of splenectomy in adult patients with immune cytopenias and identify preoperative factors associated with response. METHODS: Data from the Cleveland Clinic Foundation for 1824 patients aged over 18 who underwent splenectomy from 2002 to 2020 were analyzed...
February 2024: Journal of Internal Medicine
https://read.qxmd.com/read/37952222/production-of-recombinant-humanized-monoclonal-anti-human-neutrophil-antigen-hna-antibodies-with-potential-applicability-as-standard-antibodies
#26
JOURNAL ARTICLE
Yuko Ishimoto, Kikuyo Taniguchi, Behnaz Bayat, Ryutaro Tobita, Toru Miyazaki, Rie Onodera, Emi Kurita, Masao Kobayashi, Kazuo Muroi, Nelson Hirokazu Tsuno
BACKGROUND: Antibodies against human neutrophil antigen (HNA) are involved in the pathogenesis of neonatal alloimmune neutropenia, autoimmune neutropenia, and transfusion-related acute lung injury. The present methods for anti-HNA antibody identification strongly depend on the presence of standard antisera with known allo/isospecificities. Here, we aimed to produce recombinant humanized antibodies to HNA from available mouse monoclonal antibodies (MoAbs). STUDY DESIGN AND METHODS: RNAs were extracted from available hybridoma cells producing mouse anti-HNA antibodies recognizing HNA-1a (TAG-1), -1b (TAG-2), -2 (TAG-4), and FcγRIIIb, and the cDNA was synthesized...
November 12, 2023: Transfusion
https://read.qxmd.com/read/37920595/felty-s-syndrome
#27
REVIEW
Christoph Wegscheider, Vera Ferincz, Karin Schöls, Andreas Maieron
Felty's syndrome was first described in 1924 by the US-American physician Augustus Roi Felty as a triad of rheumatoid arthritis, splenomegaly and leucopenia. Even nearly 100 years later, this rare syndrome is still paralleled by diagnostic and therapeutic challenges and its pathogenesis is incompletely understood. Neutropenia with potentially life-threatening infections is the main problem and several pathomechanisms like Fas-mediated apoptosis, anti-neutrophil antibodies, anti-G-CSF antibodies, neutrophil consumption in the context of NETosis and suppression of granulopoiesis by T-LGLs have been suggested...
2023: Frontiers in Medicine
https://read.qxmd.com/read/37908984/lithium-monotherapy-in-graves-thyrotoxicosis
#28
James Larkworthy, Omar Kirresh, Ali Chakera, Fahad Ahmed
Lithium is not commonly used to treat thyrotoxicosis, and there are few reports in the literature of its use as initial therapy in thyrotoxicosis. We describe the case of a patient with Graves thyrotoxicosis and ophthalmopathy, on a background of autoimmune neutropenia, treated successfully with relatively long-term lithium monotherapy. Lithium was used at a lower dose and longer duration than previously reported on, to good effect. We demonstrate that lithium is an important and useful option for those who are unable to tolerate thionamide therapy...
July 2023: JCEM Case Rep
https://read.qxmd.com/read/37868579/nivolumab-induced-isolated-neutropenia
#29
Aimal Waqas, Javariya Zaffar, Ahmad Jalil, Shayan Butt
Immune checkpoint inhibitors (ICIs) have been discovered to be associated with autoimmune toxicities that may present as dermatologic, gastrointestinal, hepatic, pulmonary, endocrine, and rarely hematologic reactions. Recent studies have also discovered hematological adverse effects as a result of ICI use of which isolated neutropenia is the gravest and the rarest manifestation. Asymptomatic neutropenia cannot be ignored, and close monitoring is, at least, warranted. Severe neutropenia with neutropenic fever needs hospital admission and prompt treatment to avoid further morbidity and/or mortality...
September 2023: Curēus
https://read.qxmd.com/read/37791226/a-case-of-omphalitis-revealing-alloimmune-neonatal-neutropenia
#30
Nasa Machimoto, Yosuke Baba, Yuri Takaoka, Hiromichi Shoji, Toshiaki Shimizu
Neutropenia, characterized by a decrease in peripheral blood neutrophil count less than 1500/µL, poses significant clinical challenges due to its association with recurrent infections. This paper presents a rare and intriguing case of alloimmune neonatal neutropenia (ANN), an uncommon variant of neutropenia instigated by the transplacental transfer of maternal anti-neutrophil antibodies that consequently induce opsonization and phagocytosis of the neonate's neutrophils within the reticuloendothelial system...
August 2023: Curēus
https://read.qxmd.com/read/37773636/the-clinical-course-of-sars-cov-2-infection-in-patients-with-autoimmune-neutropenia-a-retrospective-case-series-study
#31
JOURNAL ARTICLE
Gioacchino Andrea Rotulo, Giulia Ceglie, Annalisa Candino, Antonella Merola, Elisa Profeti, Carmela Giancotta, Stefania Mercadante, Veronica Santilli, Nicola Cotugno, Paolo Palma, Giuseppe Palumbo, Andrea Finocchi
Severe acute respiratory syndrome coronavirus 2 infection in children with autoimmune neutropenia may be a cause for concern. In this retrospective study, none of the 24 autoimmune neutropenia cases manifested severe coronavirus disease 2019. We found a significant improvement in neutrophils and a reduction in lymphocytes at post-infection follow-up compared with the median of previous values. We speculate that this paradoxical effect may be due to postinfection immunological phenomena.
September 22, 2023: Pediatric Infectious Disease Journal
https://read.qxmd.com/read/37735545/paediatric-onset-evans-syndrome-breaking-away-from-refractory-immune-thrombocytopenia
#32
REVIEW
Nathalie Aladjidi, Thomas Pincez, Frédéric Rieux-Laucat, Diane Nugent
Since its first description by Evans in 1951, this syndrome has been linked to chronic immune thrombocytopenia with the concurrent or delayed onset of autoimmune haemolytic anaemia or neutropenia. For decades, the evolution of Evans syndrome (ES) has carried a poor prognosis and often resulted in chronic steroid exposure, multiple immune suppressing medications directed against T or B lymphocytes, and splenectomy. This paper presents a new view of ES based on recent advances in genomics which begin to classify patients based on their underlying molecular variants in previously described primary immune disorders...
October 2023: British Journal of Haematology
https://read.qxmd.com/read/37735323/clinical-significance-of-human-neutrophil-antigen-1-antibodies-in-children-with-neutropenia
#33
JOURNAL ARTICLE
Satoshi Goda, Shuhei Karakawa, Satoshi Okada, Hiroshi Kawaguchi, Emi Kurita, Mitsunori Noma, Aiko Yamaoka, Mayumi Komatsu, Ayaka Yanai, Mayu Kashihara, Teruhisa Fujii, Rie Onodera, Kikuyo Taniguchi, Mika Aizawa, Masao Kobayashi
Primary autoimmune neutropenia in young children is characterized by chronic neutropenia and positivity for antibodies against human neutrophil antigens (HNAs). This study analyzed the clinical characteristics of 402 children with neutropenia to identify differences between those with and without HNA-1 antibodies (HNA1abs). HNAabs in sera were detected by granulocyte immunofluorescence testing using flow cytometry. Relative fluorescence intensity (RFI) values were used to divide patients into positive (PG, n = 302), borderline (BG, n = 34), and negative (NG, n = 66) groups...
September 21, 2023: International Journal of Hematology
https://read.qxmd.com/read/37678236/obinutuzumab-in-frequently-relapsing-and-steroid-dependent-nephrotic-syndrome-in-children
#34
JOURNAL ARTICLE
Claire Dossier, Stéphanie Bonneric, Véronique Baudouin, Thérésa Kwon, Benjamin Prim, Alexandra Cambier, Anne Couderc, Christelle Moreau, Georges Deschenes, Julien Hogan
BACKGROUND: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys. METHODS: We retrospectively report 41 children with steroid-dependent or frequently relapsing nephrotic syndrome treated with a single low-dose infusion of obinutuzumab at Robert-Debre Hospital between April 2018 and December 2020...
December 1, 2023: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/37673632/-large-granular-lymphocytic-leukemia-and-its-association-with-immune-dysregulation
#35
JOURNAL ARTICLE
Fumihiro Ishida
Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disease of cytotoxic T cells or NK cells with LGL morphology and frequently complicated cytopenia and/or different autoimmune diseases, which often require medical interventions, although LGL leukemia itself is seldom lethal. Immunologic dysregulations in LGL leukemia contribute to the development of complications, for example, neutropenia with the involvement of Fas ligand system and, in pure red cell aplasia, which is a common complication among the patients of East Asian origin, impairing erythroid developments by cytotoxic T cells...
2023: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://read.qxmd.com/read/37608544/world-human-neutrophil-antigens-investigation-survey
#36
JOURNAL ARTICLE
Behnaz Bayat, Jonas Lowack, Marie Audrain, Laure Croisille, Brian Curtis, Rebecca Dangerfield, Behnaz Esmaeili, Claudia Grabowski, Margaret Keller, Hyungsuk Kim, Hartmut Kroll, Marjeta Macek Kvanka, Janette Kwok, Elyse Moritz, Oytip Nathalang, Derrick Nelson, Kaspar René Nielsen, Gail Pahn, Anthony Poles, Leendert Porcelijn, Ulrich J Sachs, Marlies Schönbacher, Günther F Körmöczi, Pawinee Kupatawintu, Daisuke Takahashi, Malgorzata Uhrynowska, Brigitte Flesch, Yoke-Lin Fung
BACKGROUND AND OBJECTIVES: Human neutrophil antigens (HNAs) are categorized into five systems: HNA-1 to HNA-5. Given the importance of neutrophils in immunity, we sought to create awareness of the role of HNA diagnostic services in managing immune neutropenia and transfusion-related acute lung injury. To provide health communities all around the world with access to these services, we conducted a survey to create a directory of these HNA diagnostic services. MATERIALS AND METHODS: An Excel table-based survey was created to capture information on the laboratory's location and was emailed to 55 individuals with known or possible HNA investigation activity...
August 22, 2023: Vox Sanguinis
https://read.qxmd.com/read/37601866/short-telomere-length-in-autoimmune-neutropenia-of-childhood-a-mere-coincidence-or-an-association
#37
Hamza S Gorsi, Maria Gallardo-Rios, Süreyya Savaşan
No abstract text is available yet for this article.
August 2023: EJHaem
https://read.qxmd.com/read/37591293/first-line-cemiplimab-monotherapy-and-continued-cemiplimab-beyond-progression-plus-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-pd-l1-50-or-more-empower-lung-1-35-month-follow-up-from-a-mutlicentre-open-label-randomised-phase-3-trial
#38
RANDOMIZED CONTROLLED TRIAL
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Xuanyao He, Manika Kaul, Emmanuel Okoye, Yuntong Li, Siyu Li, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
BACKGROUND: Cemiplimab provided significant survival benefit to patients with advanced non-small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable biomarkers at 1-year follow-up. In this exploratory analysis, we provide outcomes after 35 months' follow-up and the effect of adding chemotherapy to cemiplimab at the time of disease progression. METHODS: EMPOWER-Lung 1 was a multicentre, open-label, randomised, phase 3 trial. We enrolled patients (aged ≥18 years) with histologically confirmed squamous or non-squamous advanced non-small-cell lung cancer with PD-L1 tumour expression of 50% or more...
September 2023: Lancet Oncology
https://read.qxmd.com/read/37560548/intravenous-immunoglobulin-associated-severe-hemolytic-anemia
#39
Ojbindra Kc, Ananta Subedi, Rakshya Sharma
Intravenous immunoglobulin (IVIG) is used to treat immunodeficiency conditions, neuro-immunological, infection-related, autoimmune, and inflammatory disorders and is typically well tolerated. A hematological adverse reaction such as hemolytic anemia and neutropenia is known to occur with IVIG, which is usually transient and subclinical. However, severe hemolytic anemia is known to occur in some cases. We present a case of a 66-year-old man who developed severe symptomatic hemolytic anemia after receiving IVIG for acute inflammatory demyelinating polyneuropathy (AIDP)...
July 2023: Journal of Medical Cases
https://read.qxmd.com/read/37492787/a-woman-with-sjogren-s-syndrome-and-a-new-diagnosis-of-evans-syndrome-a-case-report
#40
Michelle A Ghebranious, Joad Eseddi, Haidy Galous
BACKGROUND: Evans syndrome (ES) is a rare disease characterized by the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES can be primary or secondary to another disease. Isolated immune cytopenias have been reported with Sjogren's syndrome (SS) in the past, but the association with ES has very rarely been reported. CASE DESCRIPTION: We present a patient with a known history of SS who presented with mild bleeding symptoms, such as heavier menses and new ecchymoses...
2023: AME Case Reports
keyword
keyword
161122
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.